Karmanos Cancer Institute Researchers Use Soy Derivative To Improve Pancreatic Cancer Treatment

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 101st Annual Meeting 2010 that shows when genistein, a component of soy, is paired with the FDA-approved drug oxaliplatin, pancreatic cancer cells become more sensitive to chemotherapy.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.